J Thorac Oncol: Long-term efficacy of nivolumab + ipilimumab in the treatment of advanced non-small cell lung cancer

In the CheckMate 227 study, compared with chemotherapy, nivolumab combined with ipilimumab can prolong the total number of patients with non-small cell lung cancer ( NSCLC ) with PD-L1 expression ≥1% Survival (OS; primary endpoint); and in a predetermined descriptive analysis, nivolumab combined with ipilimumab can also extend the overall survival of NSCLC patients with PD-L1<1%

This article reports the results of the CheckMate 227 study, which was followed up for the shortest 4 years

In this study, patients with stage IV or recurrent NSCLC who had not been treated before were randomly assigned (1:1:1) to the nivolumab combined with ipilimumab group, nivolumab group or chemotherapy group (PD- L1≥1%); or be randomly assigned to nivolumab combined with ipilimumab group, nivolumab combined with chemotherapy group or chemotherapy group (PD-L1<1%)

4-year OS rate of patients in different treatment groups

After a median follow-up of 54.

In short, in the analysis of the results of the CheckMate 227 study with the shortest follow-up of 4 years, nivolumab combined with ipilimumab as the first-line treatment for patients with advanced NSCLC has a long-lasting long-term effect when all patients have stopped immunotherapy for ≥ 2 years.

Paz-Ares Luis G, Ramalingam Suresh S, Ciuleanu Tudor-Eliade et al.